MedTrace Logo

Dose-Response Effect of Phosphatidylserine on eSport Performance

NCT07533032 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2026-04-16

No results posted yet for this study

Summary

This study will evaluate the effects of daily phosphatidylserine supplementation on electronic gaming performance, cognitive function, sleep quality, stress-related outcomes, and autonomic responses in healthy adult gamers. Participants will be enrolled in a randomized, double-blind, placebo-controlled, parallel-group study and assigned to receive placebo, 100 mg phosphatidylserine, or 200 mg phosphatidylserine daily for 6 weeks.

Outcome measures will be assessed at baseline, Week 3, and Week 6 and will include electronic gaming performance, cognitive function, visual analog scale ratings, sleep quality questionnaires, hemodynamic responses, and heart rate variability. The study is designed to determine whether daily phosphatidylserine supplementation can improve performance and selected physiological and psychological outcomes during prolonged electronic gaming sessions.

Conditions

  • Cognitive Function
  • Gaming Performance

Interventions

DIETARY_SUPPLEMENT

Placebo

Participants will ingest a placebo supplement daily for 6 weeks. The supplement will be consumed with approximately 8 ounces of water at a consistent time each day.

DIETARY_SUPPLEMENT

Phosphatidylserine (100 mg)

Participants will ingest 100 mg of phosphatidylserine daily for 6 weeks. The supplement will be consumed with approximately 8 ounces of water at a consistent time each day.

DIETARY_SUPPLEMENT

Phosphatidylserine (200 mg)

Participants will ingest 200 mg of phosphatidylserine daily for 6 weeks. The supplement will be consumed with approximately 8 ounces of water at a consistent time each day.

Sponsors & Collaborators

  • Lindenwood University

    lead OTHER

Principal Investigators

  • Chad M Kerksick, PhD · Lindenwood University

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-06-15
Primary Completion
2025-04-14
Completion
2025-04-14

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07533032 on ClinicalTrials.gov